Ly-mee G. Yu

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

Economic Evaluation of Oral Nirmatrelvir-Ritonavir for COVID-19 in Higher Risk Outpatients.

Journal: JAMA network open

Published: May 06, 2026

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients.

Journal: The New England journal of medicine

Published: April 22, 2026

Automated virtual reality therapy to treat needle fears (trypanophobia) in adolescents in England: a proof-of-concept cohort study and a Phase II randomised controlled trial.

Automated virtual reality therapy to treat needle fears (trypanophobia) in adolescents in England: a proof-of-concept cohort study and a Phase II randomised controlled trial.

Journal: EClinicalMedicine

Published: March 17, 2026

Real-world waitlist randomised controlled trial of gameChange VR to treat severe agoraphobic avoidance in patients with psychosis: a study protocol.

Real-world waitlist randomised controlled trial of gameChange VR to treat severe agoraphobic avoidance in patients with psychosis: a study protocol.

Journal: BMJ open

Published: August 17, 2025

Removal notice to "Ivermectin and COVID-19" Journal of Infection 91 (2025) 106530.

Removal notice to "Ivermectin and COVID-19" Journal of Infection 91 (2025) 106530.

Journal: The Journal of infection

Published: August 13, 2025

Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial.

Optimising Prescription of Treatment In older patients with Mild hypertension at Increased risk of Serious adverse Events (OPTIMISE2): protocol for a primary care based, open-label, randomised controlled non-inferiority trial.

Journal: Trials

Published: July 07, 2025

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK.

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK.

Journal: The lancet. Psychiatry

Published: April 11, 2025

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC).

Journal: The Lancet. Microbe

Published: March 25, 2025

Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.

Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.

Journal: Health technology assessment (Winchester, England)

Published: March 19, 2025

The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort study.

The impact of the COVID-19 pandemic on antimicrobial usage: an international patient-level cohort study.

Journal: JAC-antimicrobial resistance

Published: January 06, 2025

The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk.

The PRINCIPLE randomised controlled open label platform trial of hydroxychloroquine for treating COVID19 in community based patients at high risk.

Journal: Scientific reports

Published: December 06, 2024

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.

A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.

Journal: The Journal of infectious diseases

Published: October 17, 2024

Showing 1-12 of 147

Last Updated: 09/26/2026